Laura Aponte Becerra
Clinical FellowDownloadHi-Res Photo
About
Titles
Clinical Fellow
Departments & Organizations
Education & Training
- Residency
- University of Miami, Jackson Health System (2023)
- Research fellow
- BIDMC-BWH, Harvard Medical School (2020)
- MD
- Universidad CES (2016)
Board Certifications
Internal Medicine
- Certification Organization
- ABIM
- Original Certification Date
- 2023
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Laura Aponte Becerra's published research.
Publications Timeline
A big-picture view of Laura Aponte Becerra's research output by year.
David Roth
Gilbert Moeckel, MD, PhD, FASN
21Publications
68Citations
Publications
2024
Preemptive Kidney Transplantation Trends in Lupus
Contreras G, Pagan J, Elfassy T, Bandes M, Bustamante N, Goggins M, Becerra L, Mendoza J, Drexler Y, Alonso S, Roth D. Preemptive Kidney Transplantation Trends in Lupus. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024p18r0q9c. DOI: 10.1681/asn.2024p18r0q9c.Peer-Reviewed Original ResearchInfluenza B Triggering Atypical Hemolytic Uremic Syndrome (aHUS) in a Patient with Cobalamin C (CblC) Disease Carrier State and a Complement Factor H (CFH) Mutation
Becerra L, Moeckel G, Gunasekaran D. Influenza B Triggering Atypical Hemolytic Uremic Syndrome (aHUS) in a Patient with Cobalamin C (CblC) Disease Carrier State and a Complement Factor H (CFH) Mutation. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024vajywpws. DOI: 10.1681/asn.2024vajywpws.Peer-Reviewed Original ResearchMinimal Change Disease (MCD) and Human Chorionic Gonadotropin (hCG)-Mediated Thyrotoxicosis during Pregnancy
Becerra L, Moeckel G, Gondal M. Minimal Change Disease (MCD) and Human Chorionic Gonadotropin (hCG)-Mediated Thyrotoxicosis during Pregnancy. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024f2jtc080. DOI: 10.1681/asn.2024f2jtc080.Peer-Reviewed Original ResearchWCN24-330 TRENDS OF PREEMPTIVE KIDNEY TRANSPLANTATION IN PATIENTS APPROACHING END-STAGE RENAL DISEASE STRATIFIED BY PRIMARY DISEASE IN THE UNITED STATES FROM 1985 AND 2019
Martin G, Pagan J, Bustamante N, Ortigosa-Goggins M, Bandes M, Elfassy T, Becerra L, Mendoza J, Morales E, Drexler Y, Kupin W, Roth D. WCN24-330 TRENDS OF PREEMPTIVE KIDNEY TRANSPLANTATION IN PATIENTS APPROACHING END-STAGE RENAL DISEASE STRATIFIED BY PRIMARY DISEASE IN THE UNITED STATES FROM 1985 AND 2019. Kidney International Reports 2024, 9: s442-s443. DOI: 10.1016/j.ekir.2024.02.929.Peer-Reviewed Original ResearchEffects of Empagliflozin on the Progression of Chronic Kidney Disease
Aponte Becerra L, Turner JM. A commentary on: Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. PracticeUpdate website.Commentaries, Editorials and Letters
2023
Relationships among Non-Neoplastic Histopathological Features, Kidney Function, Proteinuria, and Other Clinical Factors in Patients Undergoing Nephrectomy
Becerra L, Betancourt J, Elfassy T, Iakymenko O, Thomas D, Isaac F, Fornoni A, Zuo Y, Barisoni L, Contreras G, Mendoza J. Relationships among Non-Neoplastic Histopathological Features, Kidney Function, Proteinuria, and Other Clinical Factors in Patients Undergoing Nephrectomy. Glomerular Diseases 2023, 3: 220-229. PMID: 37915860, PMCID: PMC10616670, DOI: 10.1159/000534339.Peer-Reviewed Original ResearchCitationsConceptsLower eGFRGlobal glomerulosclerosisInterstitial fibrosisCardiovascular diseaseClinical factorsHistopathological featuresSpecific histopathological featuresGlomerular filtration rateCross-sectional analysisDipstick proteinuriaKidney functionMultivariable analysisFiltration rateKidney parenchymaOutcome measuresProteinuriaRoutine examinationHypertensionPatientsArteriosclerosisEGFRNephrectomyObesityAssociationRegression modelsDaily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up
Becerra L, Gavrieli A, Khan F, Novak P, Lioutas V, Ngo L, Novak V, Mantzoros C. Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up. Clinical Nutrition 2023, 42: 825-834. PMID: 37084469, PMCID: PMC10330069, DOI: 10.1016/j.clnu.2023.04.008.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBody mass indexType 2 diabetesIntranasal insulinSecondary outcomesFood intakeBody compositionType 2 diabetes trialsOlder adultsPlacebo-controlled studyPlacebo-controlled trialDiabetes (ACCORD) trialPrimary outcomeIntervention visitsMass indexBody fatAnthropometric measuresAnimal studiesBody weightHigh dosesInteraction of treatmentEnergy homeostasisDiabetesInsulinWeight lossAppetiteOne-year all-cause mortality in hospitalized patients with COVID-19 and end-stage renal disease undergoing hemodialysis.
Munoz Mendoza J, Aponte-Becerra L, Torres C, Rozas J, Francois P, Salcedo J, Barreto A, Rodriguez J, Suarez M, Fornoni A, Contreras G. One-year all-cause mortality in hospitalized patients with COVID-19 and end-stage renal disease undergoing hemodialysis. Clinical Nephrology 2023, 99: 51-57. PMID: 36519940, DOI: 10.5414/cn110823.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsEnd-stage renal diseaseCOVID-19 infectionLong-term mortality riskHospital mortalityMortality riskRenal diseaseOdds ratioCOVID-19Higher long-term mortality riskRetrospective chart reviewAdjusted odds ratioLogistic regression modelsESRD patientsCause mortalitySecondary outcomesChart reviewPrimary outcomeHospitalized patientsHigher oddsMortality ratePatientsMortalityOne-yearInfectionSignificant differences
2022
Depressive symptoms exacerbate disability in older adults: A prospective cohort analysis of participants in the MemAID trial
Buss S, Becerra L, Trevino J, Fortier C, Ngo L, Novak V. Depressive symptoms exacerbate disability in older adults: A prospective cohort analysis of participants in the MemAID trial. PLOS ONE 2022, 17: e0278319. PMID: 36445876, PMCID: PMC9707770, DOI: 10.1371/journal.pone.0278319.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDepressive symptomsImportant modifiable risk factorOlder adultsWeek 48 visitModifiable risk factorsProspective cohort analysisEffect of comorbiditySelf-reported disabilityType 2 diabetesGeriatric Depression ScalePublic health priorityIntranasal insulinMedical comorbiditiesCardiovascular mortalityGait speedRisk factorsClinical trialsNormal limitsWeek 25Depression ScaleHealth priorityCohort analysisComorbiditiesWorse cognitionCognitive declineSafety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial.
Aponte Becerra L, Galindo Mendez B, Khan F, Lioutas V, Novak P, Mantzoros C, Ngo L, Novak V. Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial. Archives Of Diabetes & Obesity 2022, 4: 403-415. PMID: 35903156, PMCID: PMC9328174.Peer-Reviewed Original ResearchCitationsConceptsContinuous glucose monitoringIntranasal insulinGlycemic variabilitySystemic insulinAdverse eventsPlacebo treatmentHypoglycemic episodesWeight gainDouble-blinded placeboSerious adverse eventsDouble-blinded trialType 2 diabetesSubcutaneous insulinDiabetes burdenPlasma glucoseCapillary glucoseInsulin sensitivitySub studyLong-term effectsSafety outcomesTrial participantsGlucose metabolismShort-term effectsInsulinDiabetes